[beta(2)-Sympathomimetics: risks for asthma therapy? Lessons from the SMART1 Study. A statement from the German Respiratory Tract League].
Gillissen
A
A
Robert Koch-Klinik, Thoraxzentrum des Klinikums St. Georg, Leipzig. adrian.gillissen@sanktgeorg.de
Berdel
D
D
Buhl
R
R
Crieé
C-P
CP
Kardos
P
P
Magnussen
H
H
Rabe
K F
KF
Rolke
M
M
Vogelmeier
C
C
Worth
H
H
Virchow
J C
JC
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D001741:Black or African American; D001249:Asthma / Q000188:drug therapy* / Q000208:ethnology / Q000401:mortality; D001993:Bronchodilator Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013566:Sympathomimetics / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology; D044465:White People
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D013566:Sympathomimetics